Scynexis
SCYXScynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.
SCYX · Stock Price
Historical price data
AI Company Overview
Scynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.
Technology Platform
The 'fungerp' platform is a novel class of triterpenoid antifungal agents that inhibit glucan synthase, offering a distinct mechanism of action, fungicidal activity, and formulation flexibility (oral/IV) against a broad spectrum of resistant fungal pathogens.
Pipeline
18| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ibrexafungerp | Invasive Candidiasis | Phase 3 | |
| SCY-078 | Candidiasis, Invasive | Phase 3 | |
| Ibrexafungerp | Vulvovaginal Candidiasis | Phase 3 | |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Recurrent Vulvovaginal Candidiasis | Phase 3 | |
| SCY-078 + Fluconazole + Echinocandin | Candidiasis, Invasive | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
Scynexis competes with established antifungal classes (azoles, echinocandins) and novel agents from companies like Cidara and F2G. Its differentiation is based on the fungerp platform's novel mechanism of action, which is active against resistant strains, and its ability to deliver both oral and IV formulations, addressing a broad range of patient needs from outpatient to critically ill.